Potential Glaucoma TreatmentsNeuroprotection and NeuroregenerationCurrent treatments for glaucoma, both drugs (usually eye drops) and surgery, focus on lowering eye pressure. So researchers continue to investigate improved medications and better surgical methods aimed at decreasing eye pressure. However, vision loss in glaucoma is actually caused by damage to the optic nerve and can sometimes occur in the presence of normal or below normal eye pressure. Therefore, some current research is focused on protecting the remaining retinal ganglion cells (RGCs) in the optic nerve, called neuroprotection. Other investigators are looking at possible growth of new cells or neuroregeneration. Some scientists believe a vaccine may be able to counteract damage to the optic nerve and potentially lead to cell repair and renewal. Other research is aimed at using retinal stem cells to “grow” new RGCs to replace those that have died. Namenda® (memantine)Namenda is a drug approved by the U.S. Food and Drug Administration (FDA) to treat Alzheimer’s disease. It appears to protect the brain's nerve cells against excess amounts of glutamate, a messenger chemical released in large amounts by cells damaged by Alzheimer’s and some other neurological disorders. When glutamate attaches to the cell surface, this permits calcium to flow freely into the cell, which in turn may lead to cell degeneration. Namenda may prevent this destructive sequence by adjusting the activity of glutamate. Some researchers believed that Namenda, used in combination with eye pressure-lowering medications, might help protect cells in the optic nerve. Phase III clinical trials of Namenda have been completed, and the data is still being analyzed. The study showed that high doses of Namenda slowed progression of the disease more than low doses. However, Namenda appeared to have no benefit when compared to a placebo. The company that manufactures Namenda (Allergan, Inc.) is continuing data analysis, but does not believe the FDA will approve the drug in its present form as a glaucoma treatment. Disclaimer: The information provided in this section is a public service of the American Health Assistance Foundation, and should not in any way substitute for the advice of a qualified healthcare professional and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. The American Health Assistance Foundation does not endorse any medical product or therapy. Last Reviewed On: 11/21/08 |
American Health Assistance Foundation 
|